Track topics on Twitter Track topics that are important to you
The third Multi-stakeholder Workshop on Biosimilar Medicinal Products included a session on ‘Building Stakeholder Confidence in Biosimilar Medicines through Evidence-Based Information Sharing’ . The session focused on clinical experience of switching and clarifying definitions of ‘interchangeability’ between the US and the European Union (EU).
Original Article: Building confidence in biosimilarsNEXT ARTICLE
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...